Skip to content
deep-learning-based-computer-aided-detection-of-cerebral-microbleeds-achieves-high-sensitivity-with-a-low-false-positive-rate-in-a-confirmatory-clinical-trial-–-scientific-reports

Deep learning-based computer-aided detection of cerebral microbleeds achieves high sensitivity with a low false-positive rate in a confirmatory clinical trial – Scientific Reports

Abstract

Cerebral microbleeds (CMBs) are small, focal brain lesions recognized as critical biomarkers of cerebrovascular disease and cognitive decline. Despite advances in MRI technology, detecting CMBs remains challenging, highlighting the need for automated tools. This study aimed to evaluate the standalone performance of Neurophet SCALE MRI for automated CMB detection. The model was trained on 201 SWI and phase examinations. Neurophet SCALE MRI employs a two-stage deep learning pipeline with preprocessing steps, including reorientation, resampling, and data augmentation. In the first stage, CMB candidates are generated using a multiscale backbone and bidirectional convolutional Long Short-Term Memory. The second stage reduces false positives through a Squeeze-and-Excitation ResNet-based classifier and brain tissue segmentation. In this retrospective, single-center clinical trial, the model was tested on 457 MRI examinations. The primary endpoints were lesion-wise sensitivity (> 85.7%) and false positive rate (< 2.35 per patient). In addition, patient-wise and group-wise analyses were conducted. A total of 456 participants (224 CMB-positive, 232 CMB-negative) with 515 CMB lesions were included for the statistical analysis. The device exceeded all predefined performance criteria, demonstrating a lesion-wise sensitivity of 88.35% (95% CI: 86.61–90.17) and a false positive rate of 0.95 per patient (95% CI: 0.83–1.07). Patient-wise sensitivity and specificity were 1.0 (95% CI: 0.98–1.0) and 0.86 (95% CI: 0.81–0.90), respectively. For group-wise classification (0–4 vs. ≥5 CMBs), sensitivity and specificity were 0.91 (95% CI: 0.88–0.93) and 0.95 (95% CI: 0.74–1.0). Neurophet SCALE MRI demonstrated high sensitivity and specificity along with a low false-positive rate, supporting its potential clinical utility. Further validation by expert readers in a broader population is warranted.

Similar content being viewed by others

Acknowledgements

This research was supported by the Ministry of SMEs and Startups (MSS) and Korea Institute for Advancement of Technology (KIAT), through the Innovation Development for Global Regulation-Free Special Zone (R&D) (RS-2024-00507182).

Funding

The SCALE MRI clinical trial was sponsored by Neurophet Inc.

Author information

Author notes

  1. These authors contributed equally to this work: Hyug-Gi Kim and Eunwoo Lee.

Authors and Affiliations

  1. Department of Radiology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Korea

    Hyug-Gi Kim, Jeong Taek Yoon, Inkeon Yeo & Kyung Mi Lee

  2. Research Institute, Neurophet Inc, 314, Gangnam-daero, Gangnam-gu, Seoul, 06253, Republic of Korea

    Eunwoo Lee, Minho Lee, Sang-Yeong Jo, Danbi Song, Hanna Jang, Donghyeon Kim & Kijeong Lee

  3. Department of medicine, Graduate school, Kyung Hee University, Seoul, Korea

    Inkeon Yeo

  4. Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea

    Jin San Lee

Authors

  1. Hyug-Gi Kim
  2. Eunwoo Lee
  3. Jeong Taek Yoon
  4. Inkeon Yeo
  5. Jin San Lee
  6. Minho Lee
  7. Sang-Yeong Jo
  8. Danbi Song
  9. Hanna Jang
  10. Donghyeon Kim
  11. Kijeong Lee
  12. Kyung Mi Lee

Corresponding authors

Correspondence to Kijeong Lee or Kyung Mi Lee.

Ethics declarations

Competing interests

E.L., M.L., S-Y.J., D.S., H.J., D.K. and K.L. are current or former employees of Neurophet Inc., the manufacturer of SCALE MRI, and may hold shares or stock options in the company. The remaining authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, HG., Lee, E., Yoon, J.T. et al. Deep learning-based computer-aided detection of cerebral microbleeds achieves high sensitivity with a low false-positive rate in a confirmatory clinical trial. Sci Rep (2026). https://doi.org/10.1038/s41598-026-77551-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41598-026-77551-0

Keywords

colind88

Back To Top